UCB - Positive developments for rozanolixizumab and CIMZIA®
*The CHMP has issued a positive opinion for rozanolixizumab. If approved in Q1 2024, the drug will be the first anti-FcRn approved in Europe for both anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody-positive gMG, the two most common subtypes of gMG.*In addition, UCB released the results from a post-hoc analysis indication meaningful efficacy of CIMZIA® in rheumatoid arthritis (RA) patients with high rheumatoid factor (RF) levels.*No impact on estimates and investment case. Buy rating reiterating considering the upside to Friday's closing price (>50%). We consider the market reaction to BIMZELX® 's approval overdone: ramp-up will take time asUCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.